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Summary
 
The emergence of multidrug-resistant organisms and the failure to eradicate infection by a
number of important pathogens has led to increased efforts to develop vaccines to prevent in-
fectious diseases. However, the nature of the immune response to vaccination with a given an-
tigen can be complex and unpredictable. An example is the galactose– and 
 
N
 
-acetylgalac-
tosamine–inhibitable lectin, a surface antigen of 
 
Entamoeba histolytica
 
 that has been identified as
a major candidate in a vaccine to prevent amebiasis. Vaccination with the lectin can induce
protective immunity to amebic liver abscess in some animals, but others of the same species ex-
hibit exacerbations of disease after vaccination. To better understand this phenomenon, we
used recombinant proteins corresponding to four distinct domains of the molecule, and syn-
thetic peptides to localize both protective and exacerbative epitopes of the heavy chain subunit
of the lectin. We show that protective immunity after vaccination can be correlated with the
development of an antibody response to a region of 25 amino acid residues of the lectin, and
have confirmed the importance of the antibody response to this region by passive immuniza-
tion studies. In addition, we show that exacerbation of disease can be linked to the develop-
ment of antibodies that bind to an NH
 
2
 
-terminal domain of the lectin. These findings are clin-
ically relevant, as individuals who are colonized with 
 
E. histolytica
 
 but are resistant to invasive
disease have a high prevalence of antibodies to the protective epitope(s), compared to individ-
uals with a history of invasive amebiasis. These studies should enable us to develop an im-
proved vaccine for amebiasis, and provide a model for the identification of protective and exac-
erbative epitopes of complex antigens.
 
T
 
he intestinal protozoan parasite 
 
Entamoeba histolytica
 
 is
capable of invading and destroying human tissues,
leading to potentially life-threatening diseases such as hem-
orrhagic colitis and extraintestinal abscesses. It is estimated
that 
 
E. histolytica
 
 is responsible for about 50,000,000 cases
of invasive amebiasis annually, resulting in 100,000 deaths,
and thus rates among the leading parasitic causes of death,
surpassed only by malaria and schistosomiasis (1). Morbidity
and mortality associated with amebic infection have persisted
despite the availability of effective therapy, suggesting that
interventions designed to reduce or eliminate disease are
needed. In principle, these objectives could be achieved by
the introduction of a suitable vaccine. Since humans are the
only relevant host for 
 
E. histolytica
 
, an effective vaccination
program could potentially eradicate amebiasis.
One of the leading candidates for a vaccine to prevent
amebiasis is the galactose– and 
 
N
 
-acetylgalactosamine–inhib-
itable lectin. The structure and function of this ameba sur-
face receptor has been studied in considerable detail (for re-
view see references 2 and 3). It is a membrane-associated
glycoprotein with disulfide-linked subunits of a molecular
mass of 170 and 35 kD, respectively (4). Both subunits of
the receptor have been cloned, and their primary structures
were deduced from cDNA and genomic sequences (5–8).
The galactose– and 
 
N
 
-acetylgalactosamine–inhibitable lec-
tin appears to play a key role in amebic pathogenesis. It
mediates adherence to colonic mucins (which may be im-
portant in intestinal colonization) and mediates binding to
host cells (2, 9, 10). Adherence to host cells is critically im-
portant in the pathogenesis of intestinal disease and amebic
liver abscess, since the killing of cells by amebae is contact
dependent (3). Consistent with its role in mediating adher-
ence to target cells, antibodies to certain epitopes on the
galactose– and 
 
N
 
-acetylgalactosamine lectin can inhibit
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amebic adherence to target cells. However, it has also been
found that antibodies to other epitopes of the lectin can en-
hance binding of ameba trophozoites to mammalian cells
(11). In addition, epitopes of the lectin have been impli-
cated in cell-mediated immune responses to amebae (12),
and evidence exist that the ability of 
 
E. histolytica
 
 to resist
complement lysis is mediated by a CD59-like domain of
the ameba lectin (13).
The purified native galactose– and 
 
N
 
-acetylgalactosamine–
binding lectin has been used to vaccinate gerbils to protect
them against amebic liver abscess (14). Although vaccina-
tion was protective in most animals, in others there was ev-
idence for a significant increase in liver abscess size, sug-
gesting that the immune response to the lectin could also
exacerbate disease. Because of the vaccine potential of this
molecule and its many putative functions, we were inter-
ested in identifying protective and exacerbative epitopes of
the lectin, and in determining whether protective or exac-
erbative epitopes could be correlated with functional re-
gions of the molecule. Here we have used four nonover-
lapping recombinant proteins spanning the sequence of the
extracellular region of the heavy chain subunit of the galac-
tose–and 
 
N
 
-acetylgalactosamine–inhibitable lectin to dem-
onstrate that immunization with two of the domains can
provide protection against invasive amebiasis, that vaccina-
tion with the third domain is completely ineffective, and
that vaccination with the fourth domain actually exacer-
bates amebic liver abscess formation. Strikingly, these results
can be shown to be dependent on the antibody response,
since passive immunization of SCID mice with serum de-
rived from animals vaccinated with the individual domains
reproduces the results seen with active immunization. Us-
ing synthetic peptides we have also been able to demon-
strate that a protective immune response after vaccination
with one of the recombinant lectin domains is most likely
based on the development of an antibody response to an
epitope(s) contained within a stretch of 25 amino acid (aa)
 
1
 
residues. The clinical relevance of these data has been indi-
cated by our findings that serum samples from asymptom-
atic individuals colonized with 
 
E. histolytica
 
 who appear to
be resistant to invasive amebiasis show a high level of reac-
tivity with one of the protective domains, while only a few
individuals with a history of invasive amebiasis show anti-
bodies to this domain. Finally, we have found that one of
the protective domains of the molecule is also a potent T
cell mitogen, suggesting that it contains the carbohydrate
binding site of the ameba lectin.
 
Materials and Methods
 
Expression and Purification of Recombinant Proteins.
 
The cDNA
sequence of clone ZAP-170/4 previously isolated in our labora-
tory (5) was digested with the restriction endonucleases BglII or
Sau3A. Respective fragments encoding aa sequences 1–436, 436–
624, 799–939, and 939–1,053, respectively, were ligated into the
prokaryotic expression vector pJC20 (15) and transformed into 
 
Esch-
erichia coli
 
 strain BL21 DE3 (plys S). Expression of recombinant
proteins was achieved by induction with 0.3 mM isopropyl-
 
b
 
-
 
d
 
-
thiogalactopyranoside. Subsequently, bacteria were sedimented
and redissolved in sonication buffer (150 mM NaCl, 50 mM
Tris-HCl, pH 8.3) in the presence of 0.3 mg/ml lysozyme. After
one round of freezing and thawing, bacteria were ultrasonicated
on ice at 30 W for 10 min. The suspension was centrifuged at
8,000 
 
g
 
 for 20 min and the pellet was redissolved in sonication
buffer supplemented with 0.1% Triton X-100 followed by two
rounds of stirring at room temperature (RT) for 1 h and centrifu-
gation at 8,000 
 
g.
 
 The resulting pellet was dissolved in 
 
b
 
-mercap-
toethanol containing loading buffer, heated, and loaded onto a
continuous preparative SDS–gel electrophoresis (Prep Cell, model
491; Bio Rad Labs, Hercules, CA) using a 13% gel matrix. Mi-
grating proteins were eluted in 3-ml fractions. To remove SDS
from SDS–protein complexes, pooled fractions containing the re-
combinant proteins only were dialyzed at 4
 
8
 
C overnight against a
buffer containing 6 M guanidiniun-HCl, 50 mM NaCl, and 50
mM Tris-HCl, pH 7.5. SDS, which formed an opaque precipi-
tate, was removed by ultracentrifugation at 140,000 
 
g.
 
 The super-
natant was dialyzed extensively against 25 mM NaCl/50 mM
Tris-HCl buffer, pH 7.5, with decreasing guanidine concentra-
tion until guanidine was completely removed. Identity of the pu-
rified recombinant proteins was determined by NH
 
2
 
-terminal se-
quencing using a gas-phase protein sequencer (model 473A; Applied
Biosystems, Foster City, CA). Purity of proteins was assessed by
reversed phase HPLC.
 
ELISA for the Detection of Antilectin Antibodies in Human Sera.
 
This procedure was performed essentially as previously described
(16) using 130 ng of recombinant protein and human sera in a di-
lution of 1:400.
 
Cultivation of Cells.
 
Trophozoites of the 
 
E. histolytica
 
 isolate
HM-1:IMSS were grown axenically in TYI-S-33 medium (17).
Virulence was maintained by gerbil liver passage once per month.
For adherence assays, trophozoites in the logarithmic phase of
growth were detached by chilling of ice, pelleted by centrifuga-
tion at 500 
 
g
 
 for 5 min, washed twice with RPMI, and subse-
quently resuspended in RPMI containing 0.5% BSA and 25 mM
Hepes, pH 7.5. Chinese hamster ovary (CHO) cells were grown
in RPMI in the presence of 10% fetal calf serum, penicillin (100
U/ml), and streptomycin sulfate (100 
 
m
 
g/ml). Cells were released
by trypsinization (0.25% trypsin/EDTA; GIBCO BRL, Gaithers-
burg, MD).
 
Immunization of Rabbits and Gerbils.
 
White New Zealand rab-
bits were immunized subcutaneously with 250 
 
m
 
g of recombinant
protein emulsified in complete Freund’s adjuvants. Booster im-
munizations were performed every 14 d with the same amount of
protein using incomplete Freund’s adjuvants until a significant
antibody titer of at least 1:800 against the respective proteins was
obtained as determined by ELISA.
Adult female gerbils (
 
Meriones unguiculatus
 
) were immunized
intraperitoneally with 50 
 
m
 
g of recombinant protein emulsified
with complete Freund’s adjuvant followed by two booster immu-
nizations after 14 and 28 d, respectively, using the same amount
of protein emulsified in incomplete Freund’s adjuvants.
 
Induction of Amebic Liver Abscess in SCID Mice and Gerbils.
 
SCID mice were treated according to the method developed by
Cieslak et al. (18). Each animal received 200 
 
m
 
l of rabbit immune
or preimmune serum intraperitoneally 24 h before challenge. Pas-
sively immunized SCID mice were challenged with 10
 
6
 
 and ac-
tively immunized gerbils with 10
 
5
 
 virulent 
 
E. histolytica
 
 trophozo-
ites according to the method described by Chadee and Meerovitch
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid; CHO, Chinese hamster
ovary; RT, room temperature. 
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(19). The animals were fasted for 24 h and subsequently anesthe-
tized by intramuscular application of a combination of ketamin-
hydrochloride and xylazine. Laparatomy was performed by a ver-
tical incision of about 1 cm to visualize the liver. Amebae were
injected in a volume of 100 
 
m
 
l into the left liver lobe. Perito-
neum and abdominal wall were closed by catgut sutures and the
skin was closed using clips. 7 d later, animals were killed, and the
liver was entirely removed, sectioned, and the sizes of abscesses or
their weight relative to total liver weight was determined.
 
Solid-phase Enzyme Immunoassay for the Detection of Antibodies to
Synthetic Peptides.
 
Synthetic overlapping 170CR2-derived 25-mer
peptides were prepared by Pacemaker (Affinity Research, Exete,
U.K.). The following peptides were used: 170CR2-PEP1, NH
 
2
 
-
DPNFDCQPIECKIQEI-VITEKDGIK; 170CR2-PEP2, NH
 
2
 
-IV-
ITEKDGIKTTTVKD-GTKTTCDTN; 170CR2-PEP3, NH
 
2
 
-
DGTKTTCDTNNKRIEDARKAFIEGK; 170CR2-PEP4, NH
 
2
 
-
DARKAFIEGKEGIEQVECASTVCQN; 170CR2-PEP5, NH
 
2
 
-
VECASTVCQN-DNSCPIIADVEKCNQ; 170CR2-PEP6, NH
 
2
 
-
IIADVEKCNQNTEVDYGCKAMTGEC; 170CR2-PEP7, NH
 
2
 
-
YGCKAM-TGECDGTTYLCKFVQLTDD. Lyophilized pep-
tides were solubilized in 25 mM ammonium sulfate, pH 4.5, diluted
to a concentration of 10 
 
m
 
g/ml in PBS, and 50 
 
m
 
l/well were
coated to maxisorb microtiter plates (Nunc, Roskilde, Denmark) at
RT overnight. Plates were washed three times with PBS supple-
mented with 0.1% Tween 20. Blocking was performed with 100
 
m
 
l of PBS supplemented with 20% fetal calf serum at RT for 3 h.
Subsequently, plates were washed and the gerbil sera diluted in
PBS containing 10% fetal calf serum was added. After incubation
at RT for 2 h, plates were washed and peroxidase-conjugated
rabbit anti–hamster IgG (Dianova GmbH, Hamburg, Germany)
in a dilution of 1:600 was added and incubated at RT for 1 h.
Subsequently, plates were washed three times and the chromoge-
nic substrate 
 
o
 
-phenylendiamine was added. After incubation for
5 min, the color reactions were stopped with 2 M H
 
2
 
SO
 
4
 
 and
measured using an automatic plate reader (MR 5000; Dynatech
Labs. Inc., Chantilly, VA).
 
Adherence Assay.
 
Amebic adherence to CHO cells was per-
formed according to the method described by Ravdin and Guer-
rant (9). In brief, ameba trophozoites were washed three times in
RPMI and suspended to a final concentration of 10
 
6
 
 ml RPMI
medium containing 0.5% BSA, 2 
 
m
 
M calcein A (Calbiochem Corp.,
La Jolla, CA) and 25 mM Hepes, pH 7.5, and incubated at 37
 
8
 
C
for 15 min. After one washing, trophozoites were incubated with
the respective preimmune or immune rabbit sera on ice for 2 h.
After two washings, 10
 
4
 
 trophozoites were centrifuged together
with 10
 
6
 
 CHO cells at 150 
 
g
 
 and incubated on ice for 2 h in a
volume of 1 ml of RPMI buffer. Subsequently, rosette formation
was visualized by microscopy. Rosette formation was defined as
the percentage of ameba with at least three adherent CHO cells.
All experiments were done in duplicate and performed four
times.
 
Spleen Cell Proliferation Assay.
 
Gerbil spleen cells were prepared
and cultured in RPMI medium containing 1% 
 
l
 
-glutamine, 10%
fetal calf serum, and 50 
 
m
 
g/ml gentamicine. Gerbils were killed,
and the entire spleen was removed and transferred into 10 ml of
medium. Subsequently, the spleen was disrupted and transferred
to a tube. After 5 min, to allow pelleting of large particles, the su-
pernatant was removed, transferred to another tube, and cells were
pelleted by centrifugation with 150 
 
g
 
 at 4
 
8
 
C for 5 min. After
washing, cells were counted and transferred to 96 round-bottom
microtiter plates at a density of 2 
 
3
 
 10
 
5
 
/well. Plates were incu-
bated in a humidified atmosphere with 5% CO
 
2
 
 at 37
 
8
 
C. Recom-
binant proteins or respective controls were added and incubated
for 2 to 6 d. Subsequently, cells were pulsed with 0.4 mCi/well
[
 
3
 
H]thymidine (Amersham Corp., Arlington Heights, IL) and in-
cubated for an additional 12 h before harvesting on a filter using
an automatic cell harvester. Thymidine incorporation was deter-
mined using an automatic scintillation counter. All assays were
done in triplicates and performed three times. Culture medium,
Con A and 
 
E. histolytica
 
 membrane extract served as controls. The
latter was prepared by solubilizing of trophozoites in 0.8% octyl-
glycopuranoside and subsequent dialyzing of the lysate against PBS
containing 0.05% octylglycopuranoside.
 
Results
 
Reactivity of Human Sera to Recombinantly Expressed Polypep-
tides Derived from the E. histolytica 170-kD Lectin.
 
Based on
the main structural motifs of the 
 
E. histolytica
 
 170-kD lec-
tin, a full-length cDNA previously isolated in our labora-
tory was dissected into four nonoverlapping fragments. The
derived aa sequences of these fragments, designated r170CP,
r170PR, r170CR1, and r170CR2, respectively, represent
the NH
 
2
 
-terminal cysteine-poor region (aa residues 1–436),
the pseudorepetitive part within the cysteine-rich region
(aa residues 436–624), as well as two additional sections of
the cysteine-rich region located within the COOH-termi-
nal part of the molecule (aa residues 799–939 and 939–
1,053, respectively) (Fig. 1). The four cDNA fragments
were ligated into a prokaryotic expression vector which al-
lowed the production of high amounts of the respective
polypeptides as nonfusion proteins in 
 
E. coli.
 
 The recombi-
nant lectin fragments were purified, and samples of purity
 
.
 
95%, as determined by HPLC, were used for further ex-
periments (Fig. 1). Identity of each of the recombinant
polypeptides was confirmed by protein sequencing.
Using ELISA, a total of 109 well-defined serum samples
at a dilution of 1:400 were analyzed for their reactivity to
Figure 1. Expression and purification of recombinant fragments of the
170-kD subunit of the E. histolytica surface lectin. Shown are the struc-
tural domains of the protein as have been defined previously (12). Num-
bering refers to aa residues and indicate the boundaries of respective re-
combinant fragments. Below, expression and purification of each polypeptide
is monitored by SDS-PAGE. Lanes: a, lysate of E. coli transformed with
pJC20 (Coomassie blue stained); b, lysate of E. coli transformed with
pJC20 in which the respective lectin cDNA fragments were subcloned
(Coomassie blue stained); c, purified recombinant proteins (silver stained).
Molecular size markers are indicated on the left. 
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each of the four polypeptides. Serum samples were ob-
tained from patients with amebic disease (
 
n
 
 
 
5
 
 48) or from
asymptomatic individuals excreting 
 
E. histolytica
 
 (
 
n
 
 
 
5
 
 9). As
a control, sera from healthy, apparently uninfected individ-
uals (
 
n
 
 
 
5
 
 20) as well as from patients with miscellaneous
infectious diseases unrelated to amebiasis (
 
n
 
 
 
5
 
 32) were in-
cluded. Sera were collected from European individuals as
well as from those living in areas endemic for amebiasis.
The outcome of the assays is shown in Table 1. Depending
on the antigen used, the results obtained differed substan-
tially. All 48 serum samples (100%) collected from patients
with amebic disease reacted with the NH
 
2
 
-terminal cys-
teine-poor region (r170CP), whereas a reduced number
did so with the other three recombinant antigens (56% with
170PR, 77% with r170CR1, and 10% with r170CR2).
When compared with the 52 control sera, specificity for
the detection of antiamebic antibodies was high and ex-
ceeded 94% with three of the four polypeptides. On the
other hand, specificity was only 77% using r170PR as the
antigen, suggesting that the pseudorepetitive region shares
some common epitopes which are recognized by a substan-
tial number of human sera. This result may explain previ-
ous findings, indicating that 
 
z
 
25% of sera from individuals
apparently not infected with 
 
E. histolytica
 
 recognize the pu-
rified, natural lectin molecule (20). Besides the differences
between the four recombinant antigens concerning sensi-
tivity and specificity for the detection of antiamebic anti-
bodies, a more striking finding became evident by compar-
ing the reactivities between sera collected from patients
with amebic disease and those from asymptomatic E. his-
tolytica carriers. Sera of both groups reacted to a similar ex-
tent with r170CP, r170PR, and r170CR1, but a marked
difference was found for r170CR2. This polypeptide was
recognized by 78% of sera from asymptomatic carriers, but
only by 10% of sera from amebiasis patients (P ,0.001).
Immunogenicity and Vaccine Efficacy of Recombinant Proteins
in Gerbils. Adult female gerbils were immunized intraperi-
toneally with three doses of 50 mg each of the respective
recombinant antigen, emulsified in complete or incomplete
Freund’s adjuvants. As a control, animals were immunized
using Freund’s adjuvants only. A total of three trials were
performed, each comprising four to seven animals. Subse-
quently, specific antibodies were determined indicating that
none of the controls, but all of the animals immunized with
recombinant protein, developed a significant serum IgG
antibody response to the respective antigen. Challenge of
these animals by liver inoculation with 105 virulent E. his-
tolytica trophozoites showed clear differences between the
groups. As shown in Table 2, all of the 17 sham-immu-
nized control animals developed liver abscesses, whereas
immunization with either r170PR or r170CR2 revealed
total protection against liver abscess formation in 6 out 16
(37.5%) and 10 out of 16 (62.5%) gerbils, respectively, as
well as significant reductions in the size of abscesses in the
remaining animals. Immunization of gerbils using the NH2-
terminal cysteine-poor region of the lectin (r170CP) gave
Table 1. Recognition of Different Recombinant Fragments of the E. histolytica Galactose-inhibitable Surface Lectin by Human Sera
Apparently no
E. histolytica infection
Symptomatic
E. histolytica infection
Asymptomatic
E. histolytica infection
r170CP 1/52 (2%) 48/48 (100%) 8/9 (89%) (P 5 0.16)*
r170PR 12/52 (23%) 27/48 (56%) 4/9 (44%) (P 5 0.39)
r170CR1 0/52 (0%) 37/48 (77%) 6/9 (67%) (P 5 0.39)
r170CR2 3/52 (6%) 5/48 (10%) 7/9 (78%) (P ,0.001)
*P values between sera of patients with symptomatic and asymptomatic E. histolytica infection as determined by Fisher’s exact test.
Table 2. Protection of Gerbils from Amebic Liver Abscess by Vaccination with Recombinantly Expressed Fragments of the 170-kD Lectin
Vaccine group
No. of gerbils with liver abscess/
No. of gerbils challenged Percent protected Size of liver abscesses
mm mean 6 SD
Buffer 17/17 (5/5, 5/5, 7/7) 0.0 6 6 2
r170CP 15/16 (3/4, 5/5, 6/6) 6.7 9 6 3*
r170PR 10/16 (3/5, 3/4, 4/7) 37.5 (P ,0.05) 3 6 2*
r170CR1 8/9 (4/5, 4/4) 11.1 5 6 3
r170CR2 6/16 (2/5, 1/4, 3/7) 62.5 (P ,0.001) 3 6 1*
*Significant difference from buffer control (P ,0.05) as determined by Fisher’s exact test.1797 Lotter et al.
no protection and resulted in a significant increase in size of
abscesses. Immunization with r170CR1 revealed neither
protection nor a change in size of abscesses compared to
controls. Titration of each of the various gerbil antisera
against the respective antigen revealed no correlation be-
tween titer of antibodies and degree of protection.
Seroreactivity of r170CR2-immunized Gerbils to 170CR2-
derived Synthetic Peptides. To determine whether the high
degree of vaccine efficacy obtained by immunization of ger-
bils with r170CR2 could be mapped to a specific epitope, a
set of seven overlapping peptides was synthesized spanning
the entire 115 aa of the 170CR2 region. Each peptide con-
sisted of 25 aa. Reactivity to each of the seven synthetic
peptides was determined for each of the 16 sera collected
from the gerbils that had been immunized with r170CR2
(Fig. 2). Irrespective of whether sera were taken from ger-
bils that had developed abscesses, or from those that were
protected, the two groups reacted to a similar extent with
six of the seven peptides. High antibody titers were found
against peptide 3 and 4, but none of the sera reacted with
peptide 2. In contrast, a highly significant difference between
the two groups of animals was found in response to peptide
5 (P ,0.001). None of the sera obtained from the six ger-
bils that had developed abscesses reacted with this peptide,
even at the lowest dilution tested (1:100). In contrast, 9 out
of the 10 animals that did not develop liver abscesses showed
significant antibody titers against peptide 5. Two of the
nine serum samples reacted at dilutions up to 1:200 and
1:400, respectively, and the remaining seven reacted at di-
lutions of at least 1:800 and some of them even at dilutions
of up to 1:12,800.
Passive Transfer Studies in SCID Mice. To further validate
the role of antibodies directed to the various regions of the
170-kD lectin in exacerbation or protection of disease, we
performed passive immunization studies in SCID mice.
Polyclonal rabbit antisera against the recombinant polypep-
tides were transferred into SCID mice 24 h before intrahe-
patic challenge with 106 virulent E. histolytica trophozoites.
The antisera were generated by immunization of rabbits
with r170CP, r170PR, and r170CR2, respectively. Booster
immunizations were performed until antisera reacted to the
respective antigen in a dilution of at least 1:1,600. Titration
of the antiserum obtained from the r170CR2-immunized
rabbit against the different synthetic peptides revealed high
antibody titers against peptides 1, 3, 4, 6, and 7, respec-
tively, but apparently no antibodies against peptide 2 and
only a rather low antibody titer against peptide 5, which
did not exceed 1:200 even after several booster immuniza-
Figure 2. Seroreactivity of r170CR2-immunized gerbils to 170CR2-
derived synthetic peptides. 16 gerbils were immunized with r170CR2 be-
fore challenge with virulent E. histolytica trophozoites. 6 of them devel-
oped abscesses, whereas 10 of them were found to be protected. Shown
are antibody titers of the 16 gerbil immune sera to each of the seven over-
lapping 25-mer peptides (170CR2-pep1–7) spanning the entire 115 aa
residues of 170CR2. Open boxes, sera that did not react with respective
peptides at serum dilutions below 1:200; gray boxes, sera reactive at dilu-
tions between 1:200 and 1:800; and filled boxes, sera reactive at dilutions
above 1:800.
Table 3. Protection of SCID Mice from Amebic Liver Abscess by Transfer of Rabbit Antisera Raised against Recombinantly Expressed 
Fragments of the 170-kD Lectin
Vaccine group
No. of SCID mice with liver abscess/
No. of SCID mice challenged Percent protected
Percent liver abscessed in
nonprotected mice
mean 6 SD
Preimmune 19/19 (4/4, 5/5, 5/5, 5/5) 0.0 17.1 6 7.8
Anti-r170CP 8/8 (5/5, 3/3) 0.0 28.2 6 12.6*
Anti-r170PR 5/8 (3/5, 2/3) 37.5 3.2 6 1.2*
Anti-r170CR2a 8/8 (5/5, 3/3) 0.0 7.6 6 3.8*
Anti-r170CR2a‡ 2/5 (2/5) 60.0 5.5
Anti-r170CR2b 2/5 (2/5) 60.0 9.3
Anti-r170CR2c 3/5 (3/5) 40.0 8.3
Anti-r170CR2a‡ 1 b 1 c 7/15 (2/5, 2/5, 3/5)  53.3 7.7 6 1.8*
*Significant difference from preimmune control (P ,0.05), as determined by Fisher’s exact test.
‡53 concentrated anti-r170CR2a antiserum with low antibody titer to peptide 5.1798 Antibody-mediated Protection against Invasive Amebiasis
tions. Therefore, two additional rabbits were immunized
with r170CR2. Fortunately, both developed substantial an-
tibody titers to peptide 5 reacting at dilutions of up to 1:800
and 1:3,200, respectively. The various rabbit antisera, as
well as respective preimmune control sera, were used for
passive immunization in SCID mice. In addition, a 53
concentrated sample of the anti-r170CR2 antiserum which
exhibited a low antibody titer to peptide 5 was included.
As shown in Table 3, all of the 19 control animals, as well
as all 8 mice which received anti-r170CP antiserum, devel-
oped amebic abscesses. The sizes of abscesses in the anti-
r170CP group were significantly larger (P ,0.05) than
those seen in the control animals, indicating that antibodies
to the cysteine-poor region are exacerbating disease. In
contrast, anti-r170PR and anti-r170CR2 antisera conferred
total protection against liver abscess formation in 37.5 and
53.3% of mice, respectively. In addition, the sizes of ab-
scesses in the remaining mice of these two groups were sig-
nificantly smaller compared to controls. Interestingly, all
eight SCID mice which received nonconcentrated anti-
r170CR2 antiserum containing low amounts of antibodies
to peptide 5 developed abscesses. However these abscesses
were significantly smaller than those of controls (Table 3).
Inhibition of E. histolytica Adherence by Antisera. Rabbit an-
tisera  raised against the four recombinant polypeptides, as
well as respective preimmune control sera, were investi-
gated for their ability to inhibit adherence of E. histolytica
trophozoites to CHO cells using a standard in vitro roset-
ting assay (Fig. 3). The results obtained indicated that com-
pared to controls, all of the immune sera were able to sub-
stantially inhibit adherence at low serum dilutions of 1:10.
However, at higher dilutions of 1:100 or 1:1,000, this in-
hibitory effect was no longer detectable with anti-r170CR1
or anti-r170CR2. In contrast, anti-r170PR at dilutions of
1:100 or 1:1,000 strongly inhibited adherence by 81 and
75%, respectively. A rather unusual effect was obtained us-
ing the antiserum raised against the NH2-terminal part of
the lectin (anti-r170CP). Inhibition of adherence was only
22% at a serum dilution of 1:100, but increased to 77% at a
dilution of 1:1,000.
Induction of Spleen Cell Proliferation. Previous studies have
indicated that amebic cell extracts are able to stimulate cell
proliferation (21), and that the galactose-inhibitable lectin is
responsible for this activity (22). Therefore, we investigated
cultures of spleen cells isolated from naive gerbils for their
ability to proliferate in response to incubation with the re-
combinant polypeptides. As shown in Fig. 4, cells prolifer-
ated in the presence 30 mg/ml of E. histolytica membrane
extracts, as well as in the presence of 2.5 mg/ml of r170PR,
whereas no stimulation was achieved using the other three
recombinant polypeptides. The main proliferative response
was obtained within the first 48 h of incubation, and was
comparable to the stimulation seen with the plant lectin
concavalin A. Nonspecific stimulation which might be due
to contamination by LPS was excluded since all preparations
were found to contain less than 52 pg/ml of LPS, which is
below the amount necessary to induce lymphocyte prolif-
eration. In addition, specificity of proliferation by r170PR
was further supported by the fact that treatment of the
polypeptide with proteinase K, and subsequently with PMSF,
completely inhibited stimulation, whereas control cells in-
cubated with proteinase K and PMSF were not altered and
could be stimulated by concavalin A.
Discussion
We made use of recombinantly expressed fragments of
the E. histolytica 170-kD lectin to identify and characterize
Figure 3. Inhibition of amebic adherence to CHO cells by antisera to
recombinant antigens. E. histolytica trophozoites were treated with rabbit
sera raised against recombinant polypeptides before incubation with
CHO cells. Subsequently, the number of amebae with at least three ad-
herent CHO cells (rosettes) was determined. Results were compared with
those obtained with respective preimmune controls. Bars represent per-
centage of rosettes relative to respective controls at serum dilutions as in-
dicated. Error bars represent standard deviations of four experiments per-
formed in duplicate.
Figure 4. Proliferation of spleen cells isolated from naive (open bars) or
immunized gerbils (closed bars) in response to recombinant antigens. Re-
spective spleen cells were incubated in the presence of 2.5 mg/ml of the
various recombinant polypeptides and blastogenesis was determined by
[3H]thymidine uptake after 3 d (naive spleen cells) or 5 d (primed spleen
cells) of incubation. The results are expressed as means of three experi-
ments performed in triplicate with spleen cells of at least five animals.
Culture medium, Con A, and E. histolytica membrane extract served as
controls. The latter was used in a concentration of 30 mg/ml.1799 Lotter et al.
regions that might be suitable for use as a subunit vaccine
against invasive amebiasis. A total of four separate fragments
were investigated spanning almost the entire extracellular
portion of the molecule. In contrast to previous publica-
tions using recombinant E. histolytica lectin, the polypep-
tides we used were expressed as nonfusion proteins, highly
purified, and renatured by extensive dialysis against buffer,
thus eliminating all of the detergent necessary to initially
solubilize the recombinant proteins from E. coli lysates.
Therefore, results obtained in this study may not necessarily
complement those reported previously.
Depending on the polypeptide used, immunization of
gerbils and subsequent liver inoculation of live E. histolytica
trophozoites resulted either in protection against liver ab-
scess formation or in development of enlarged abscesses.
These effects were found to be mediated by specific anti-
bodies, as evidenced by passive transfer experiments with
respective antisera using the SCID mouse model. Previous
vaccination trials in gerbils with purified, native E. histolyt-
ica lectin had revealed two different groups of responders.
After challenge with E. histolytica trophozoites, 67% of im-
munized animals were found to be protected, whereas the
remaining 33% developed larger abscesses compared to sham-
immunized controls (14). Our results indicate that antibod-
ies directed against the NH2-terminal, cysteine-poor region
of the lectin (r170CP) are responsible for the formation of
larger abscesses, which might be due to antibodies reacting
with adherence-enhancing epitopes. The presence of such
epitopes on the ameba lectin has already been demon-
strated using monoclonal antibodies (11, 23). In addition, it
was reported that 36% of sera from patients with invasive
amebiasis which had developed high antibody titers against
the native E. histolytica lectin were found to increase adher-
ence of the amebae to CHO cells (11). However, our in
vitro studies on adherence of E. histolytica trophozoites to
CHO cells did not reveal enhanced adherence in response
to anti-r170CP antiserum. This antiserum strongly inhib-
ited adherence at a dilution of 1:1,000 but interestingly, in-
hibition was drastically reduced at a dilution of 1:100. There-
fore, we speculate that the anti-r170CP antiserum used in
this study contains both adherence-enhancing, as well as
adherence-inhibiting antibodies, which may compete for
binding to the lectin, or which are present in different
quantities, or bind with different affinity. Further dissec-
tions of r170CP will help to identify the epitope(s) respon-
sible for exacerbation of amebic disease. Nevertheless, in-
duction of larger abscesses by immunization with r170CP
excludes this part of the lectin for use in a subunit vaccine.
In contrast to the NH2-terminal, cysteine-poor part of
the lectin, immunization of gerbils with the pseudorepeti-
tive fragment of the cysteine-rich region (r170PR) or trans-
fer of respective antibodies into SCID mice mediated some
degree of protection against liver abscess formation. Most
of the animals (62.5%) developed significantly smaller ab-
scesses compared to respective controls, and the remaining
showed no abscesses at all. Most notably, none of them de-
veloped larger abscesses. Our in vitro results indicate that
r170PR has cell-binding activity. In contrast to the other
recombinant fragments, r170PR was found to specifically
induce proliferation of nonprimed (naive) gerbil spleen
cells, an effect comparable with that of the plant lectin Con
A. Therefore, the pseudorepetitive part of the cysteine-rich
region is likely to contain the sugar-binding domain, which
is in line with the result that anti-r170PR antiserum strongly
inhibited adherence of amebae to CHO cells. A number of
monoclonal antibodies reacting with the ameba lectin have
been reported (11, 23). All of them map to the cysteine-
rich region. Three of them, which map to different frag-
ments, were found to inhibit ameba adherence to CHO
cells. According to the primary sequence, these fragments
are separated by some hundred aa residues. Whether the
three monoclonal antibodies map to different binding do-
mains that may be located on the lectin or whether they in-
duce a conformational change of the molecule has not been
established. Nevertheless, one of the adherence inhibiting
monoclonal antibodies maps to a fragment that overlaps with
170PR (23). Although a lectin fragment that contains the
sugar-binding domain would appear to be an ideal candi-
date for an amebiasis vaccine, the use of r170PR might be
disadvantageous because of its ability to induce spleen cell
proliferation.
Highest vaccine efficacy was obtained by immunization
with r170CR2, the relatively COOH-terminal–located,
cysteine-rich fragment (amino acids [aa] 939–1053). From
the 16 gerbils immunized with r170CR2, 62.5% were com-
pletely protected against amebic liver abscess formation, the
size of abscesses in the remaining gerbils was significantly
smaller, and none had larger abscesses compared to controls.
In contrast, the results obtained by immunization with
r170CR1 (aa 799–939) were identical to those of controls.
Therefore, the cysteine-rich part of the lectin conferring
protection can now be restricted to a region of 115 aa resi-
dues covered by 170CR2. The degree of protection by im-
munization with r170CR2 was comparable with those ob-
tained in previous studies. Vaccinations of gerbils using a
glutathione S transferase fusion protein containing most of
the cysteine-rich, nonrepetitive region of the lectin (aa
649–1202) had revealed 81% vaccine efficacy (24), and
LC3, a 52-kD histidine-tailed fragment of the cysteine-rich
region (aa 785–1134) was found to protect 71% of immu-
nized gerbils (25). In these two studies, a reduction in the
sizes of abscesses in the nonprotected animals was not re-
ported, although gerbils were killed and analyzed for liver ab-
scess formation 14 d after challenge. In our study, vaccine
efficacy was determined at day 7 after challenge. Since un-
treated animals are able to reverse some degree of pathol-
ogy (19, 26), it might be possible that small abscesses would
be cleared within the following 7 d and thus, the number
of gerbils without abscesses may have increased in our
study.
As in the aforementioned studies, we found no correla-
tion between the degree of protection and the titer of an-
tibodies using the recombinant polypeptides as antigen.
However, further analysis of the antibody response against
r170CR2 using 25-mer peptides as well as our passive
transfer experiments in SCID mice revealed a strong corre-1800 Antibody-mediated Protection against Invasive Amebiasis
lation between degree of protection and titer of antibodies
to the sequence NH2-VECASTVCQNDNSCPIIADVE-
KCNQ representing aa residues 999–1,023 of the 170-kD
lectin.
Questions remain open about the mechanism by which
antibodies to 170CR2-derived epitopes confer protection.
Our results suggest that 170CR2 is not involved in adher-
ence, thus an adherence-inhibiting effect can be excluded.
Therefore, other functions that might be located on the
lectin may be altered by anti-r170CR2 antibodies. Besides
adherence, at least two additional functions have been con-
sidered to be present on the ameba lectin. Using mono-
clonal antibodies, fragments of the lectin have been identi-
fied that are involved in mediating (a) resistance of amebae
to human complement (13), and (b) stimulation of tumor
necrosis factor–a production by macrophages (12). In addi-
tion, one monoclonal antibody which did not inhibit ad-
herence was found to decrease ameba-induced cell killing
(23). Although the various antibodies recognized different
epitopes, all of them map to fragments that overlap with
170CR2. Since all of the functions are strongly associated
with the survival of E. histolytica trophozoites within the
tissues, antibodies to 170CR2 may result in an accelerated
clearance of the ameba from the tissues. Therefore, r170CR2
might constitute a vaccine which most likely will prevent
amebic disease rather than preventing amebic colonization
of the intestine. This assumption would be consistent with
our finding that in contrast to patients with amebic disease,
most of the asymptomatic E. histolytica carriers have signifi-
cant antibody titers to r170CR2. Unfortunately, only nine
samples from asymptomatic carriers could be included in
our study, since those individuals are extremely rare. Nev-
ertheless, even with the small number of samples, the re-
sults obtained were highly significant (P ,0.001), suggest-
ing that antibodies to r170CR2 are able to confer protection
against invasive amebiasis, not only in artificially infected
rodents, but also in naturally infected humans. Further analy-
ses of r170CR2 and, in particular, immunization studies in
monkeys will prove whether this polypeptide constitutes a
suitable subunit vaccine to prevent invasive amebiasis in
primates.
The work we have outlined here describes a successful
approach to identifying both protective and exacerbative
epitopes from the galactose– and N-acetylgalactosamine–
inhibitable lectin, a major candidate in a vaccine for amebi-
asis. As efforts to develop vaccines for a variety of infectious
and noninfectious diseases continues, we anticipate that other
antigens will be found that induce complex immune re-
sponses, resulting either in protective immunity or exacer-
bating disease. A key element in understanding these re-
sponses and designing better vaccines will be the ability to
identify, at the peptide level, the location of protective and
exacerbative epitopes.
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